Our results show that probiotic treatment to inhibit the expression of PD-L1 could be used as an adjuvant treatment with immune checkpoint inhibitors to improve the efficacy of anti-cancer drugs and the patient’s overall prognosis. This evidence concerns the gene CD274 and cancer.